Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 892

1.

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group.

Lancet. 2018 Nov 15. pii: S0140-6736(18)32752-1. doi: 10.1016/S0140-6736(18)32752-1. [Epub ahead of print]

PMID:
30449623
2.

Fitness costs associated with multiple resistance to dicamba and atrazine in Chenopodium album.

Ghanizadeh H, Harrington KC.

Planta. 2018 Nov 7. doi: 10.1007/s00425-018-3040-5. [Epub ahead of print]

PMID:
30406410
3.

Association of community food environment and obesity among US adults: a geographical information system analysis.

Chen M, Creger T, Howard V, Judd SE, Harrington KF, Fontaine KR.

J Epidemiol Community Health. 2018 Nov 5. pii: jech-2018-210838. doi: 10.1136/jech-2018-210838. [Epub ahead of print]

PMID:
30397025
4.

Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial.

Bahig H, Yuan Y, Mohamed ASR, Brock KK, Ng SP, Wang J, Ding Y, Hutcheson K, McCulloch M, Balter PA, Lai SY, Al-Mamgani A, Sonke JJ, van der Heide UA, Nutting C, Li XA, Robbins J, Awan M, Karam I, Newbold K, Harrington K, Oelfke U, Bhide S, Philippens MEP, Terhaard CHJ, McPartlin AJ, Blanchard P, Garden AS, Rosenthal DI, Gunn GB, Phan J, Cazoulat G, Aristophanous M, McSpadden KK, Garcia JA, van den Berg CAT, Raaijmakers CPJ, Kerkmeijer L, Doornaert P, Blinde S, Frank SJ, Fuller CD.

Clin Transl Radiat Oncol. 2018 Aug 24;13:19-23. doi: 10.1016/j.ctro.2018.08.003. eCollection 2018 Nov.

5.

High-resolution air-clad imaging fibers.

Wood HAC, Harrington K, Birks TA, Knight JC, Stone JM.

Opt Lett. 2018 Nov 1;43(21):5311-5314. doi: 10.1364/OL.43.005311.

PMID:
30383002
6.

Program-Level Factors Influencing Positive Graduate Outcomes of Physical Therapy Residency Programs.

Hartley GW, Roach KE, Harrington KL, McNally S.

Phys Ther. 2018 Oct 17. doi: 10.1093/ptj/pzy125. [Epub ahead of print]

PMID:
30329121
7.

Patritumab with Cetuximab Plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase-Ib Study.

Dillon MT, Grove L, Newbold KL, Shaw H, Brown NF, Mendell J, Chen S, Beckman RA, Jennings A, Ricamara M, Greenberg J, Forster M, Harrington KJ.

Clin Cancer Res. 2018 Oct 16. pii: clincanres.1539.2018. doi: 10.1158/1078-0432.CCR-18-1539. [Epub ahead of print]

PMID:
30327312
8.

The Burden of Frailty Among U.S. Veterans and Its Association With Mortality, 2002-2012.

Orkaby AR, Nussbaum L, Ho YL, Gagnon D, Quach L, Ward R, Quaden R, Yaksic E, Harrington K, Paik JM, Kim DH, Wilson PW, Gaziano MJ, Djousse L, Cho K, Driver JA.

J Gerontol A Biol Sci Med Sci. 2018 Oct 11. doi: 10.1093/gerona/gly232. [Epub ahead of print]

PMID:
30307533
9.

Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT).

Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J.

Ann Oncol. 2018 Oct 8. doi: 10.1093/annonc/mdy423. [Epub ahead of print]

PMID:
30295695
10.

APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.

Huff AL, Wongthida P, Kottke T, Thompson JM, Driscoll CB, Schuelke M, Shim KG, Harris RS, Molan A, Pulido JS, Selby PJ, Harrington KJ, Melcher A, Evgin L, Vile RG.

Mol Ther Oncolytics. 2018 Aug 29;11:1-13. doi: 10.1016/j.omto.2018.08.003. eCollection 2018 Dec 21.

11.

Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).

Nutting CM, Morden JP, Beasley M, Bhide S, Cook A, De Winton E, Emson M, Evans M, Fresco L, Gollins S, Gujral D, Harrington K, Joseph M, Lemon C, Luxon L, van den Blink Q, Mendes R, Miah A, Newbold K, Prestwich R, Robinson M, Sanghera P, Simpson J, Sivaramalingam M, Srihari NN, Sydenham M, Wells E, Witts S, Hall E; COSTAR Investigators.

Eur J Cancer. 2018 Nov;103:249-258. doi: 10.1016/j.ejca.2018.08.006. Epub 2018 Oct 1.

12.

Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults.

Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith SR, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P; AIBL Research Group.

Arch Clin Neuropsychol. 2018 Oct 1. doi: 10.1093/arclin/acy078. [Epub ahead of print]

PMID:
30272115
13.

Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.

Allin DM, Shaikh R, Carter P, Thway K, Sharabiani MTA, Gonzales-de-Castro D, O'Leary B, Garcia-Murillas I, Bhide S, Hubank M, Harrington K, Kim D, Newbold K.

Eur J Cancer. 2018 Nov;103:165-175. doi: 10.1016/j.ejca.2018.08.013. Epub 2018 Sep 22.

PMID:
30253333
14.

Improving Inpatient Asthma Management: The Implementation and Evaluation of a Pediatric Asthma Clinical Pathway.

Magruder TG, Narayanan S, Walley S, Powers T, Whitlock H, Harrington K, Wall TC.

Pediatr Qual Saf. 2017 Aug 22;2(5):e041. doi: 10.1097/pq9.0000000000000041. eCollection 2017 Sep-Oct.

15.

Affibody-based PET imaging to guide EGFR-targeted cancer therapy in head and neck squamous cell cancer models.

Burley TA, Pieve CD, Martins CD, Ciobota DM, Allott L, Oyen WJG, Harrington KJ, Smith G, Kramer-Marek G.

J Nucl Med. 2018 Sep 13. pii: jnumed.118.216069. doi: 10.2967/jnumed.118.216069. [Epub ahead of print]

PMID:
30213849
16.

Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults.

Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith S, Robertson J, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P; AIBL Research Group.

J Alzheimers Dis. 2018;65(4):1313-1325. doi: 10.3233/JAD-180507.

PMID:
30149452
17.

Patient-reported outcomes with nivolumab in advanced solid cancers.

Tykodi SS, Schadendorf D, Cella D, Reck M, Harrington K, Wagner S, Shaw JW.

Cancer Treat Rev. 2018 Nov;70:75-87. doi: 10.1016/j.ctrv.2018.08.001. Epub 2018 Aug 2. Review.

18.

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTErAMG 330.

Laszlo GS, Beddoe ME, Godwin CD, Bates OM, Gudgeon CJ, Harrington KH, Walter RB.

Haematologica. 2018 Aug 16. pii: haematol.2018.202069. doi: 10.3324/haematol.2018.202069. [Epub ahead of print] No abstract available.

19.

Women in academic musculoskeletal radiology.

Harrington KA, Chang G.

Clin Imaging. 2018 Jul 29;52:180-182. doi: 10.1016/j.clinimag.2018.07.022. [Epub ahead of print]

PMID:
30096557
20.

Ultrahigh Dose-rate Radiotherapy: Next Steps for FLASH-RT.

Harrington KJ.

Clin Cancer Res. 2018 Aug 9. doi: 10.1158/1078-0432.CCR-18-1796. [Epub ahead of print]

PMID:
30093447
21.

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.

Dillon MT, Boylan Z, Smith D, Guevara J, Mohammed K, Peckitt C, Saunders M, Banerji U, Clack G, Smith SA, Spicer JF, Forster MD, Harrington KJ.

Clin Transl Radiat Oncol. 2018 Jun 8;12:16-20. doi: 10.1016/j.ctro.2018.06.001. eCollection 2018 Aug.

22.

Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status.

Hafsi H, Dillon MT, Barker HE, Kyula JN, Schick U, Paget JT, Smith HG, Pedersen M, McLaughlin M, Harrington KJ.

Front Oncol. 2018 Jul 13;8:245. doi: 10.3389/fonc.2018.00245. eCollection 2018.

23.

Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease.

Harrington KD, Schembri A, Lim YY, Dang C, Ames D, Hassenstab J, Laws SM, Rainey-Smith S, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P; AIBL Research Group.

Neurobiol Aging. 2018 Oct;70:170-179. doi: 10.1016/j.neurobiolaging.2018.06.005. Epub 2018 Jun 11.

PMID:
30015036
24.

Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.

Tree AC, Jones K, Hafeez S, Sharabiani MTA, Harrington KJ, Lalondrelle S, Ahmed M, Huddart RA.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1168-1171. doi: 10.1016/j.ijrobp.2018.04.070. Epub 2018 May 4.

25.

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.

Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, Butler R, Shafren D, Au G, Knowles M, Harrington K, Vile R, Melcher A, Pandha H.

Mol Ther Oncolytics. 2018 Feb 14;9:1-12. doi: 10.1016/j.omto.2018.02.001. eCollection 2018 Jun 29.

26.

Harness the power of groups to beat the 'PhD blues'.

Harrington K.

Nature. 2018 Jul;559(7712):143-144. doi: 10.1038/d41586-018-05589-w. No abstract available.

PMID:
29968835
27.

Moth-inspired navigation algorithm in a turbulent odor plume from a pulsating source.

Liberzon A, Harrington K, Daniel N, Gurka R, Harari A, Zilman G.

PLoS One. 2018 Jun 13;13(6):e0198422. doi: 10.1371/journal.pone.0198422. eCollection 2018.

28.

Modeling Child-Nature Interaction in a Nature Preschool: A Proof of Concept.

Kahn PH Jr, Weiss T, Harrington K.

Front Psychol. 2018 May 29;9:835. doi: 10.3389/fpsyg.2018.00835. eCollection 2018.

29.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

PMID:
29884413
30.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.

PMID:
29866947
31.

An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.

Henderson DR, Murray JR, Gulliford SL, Tree AC, Harrington KJ, Van As NJ.

Clin Oncol (R Coll Radiol). 2018 Sep;30(9):539-547. doi: 10.1016/j.clon.2018.05.001. Epub 2018 May 25.

PMID:
29807801
32.

Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams).

Grønhøj C, Jensen DH, Dehlendorff C, Marklund L, Wagner S, Mehanna H, Munck-Wikland E, Ramqvist T, Näsman A, Wittekindt C, Würdemann N, Sharma SJ, Gattenlöhner S, Kiss K, Andersen E, Spruce R, Batis N, Robinson M, Harrington K, Winter S, Jones TM, Klussmann JP, Dalianis T, Friborg J, von Buchwald C.

Br J Cancer. 2018 Jun;118(12):1672-1681. doi: 10.1038/s41416-018-0107-9. Epub 2018 May 24.

PMID:
29795309
33.

Baseline Psychosocial Characteristics Predict Frequency of Continuous Glucose Monitoring in Youth with Type 1 Diabetes.

McGill DE, Volkening LK, Butler DA, Harrington KR, Katz ML, Laffel LM.

Diabetes Technol Ther. 2018 Jun;20(6):434-439. doi: 10.1089/dia.2018.0037. Epub 2018 May 4.

PMID:
29727245
34.

Synergistic antitumour effects of rapamycin and oncolytic reovirus.

Comins C, Simpson GR, Rogers W, Relph K, Harrington K, Melcher A, Roulstone V, Kyula J, Pandha H.

Cancer Gene Ther. 2018 Jun;25(5-6):148-160. doi: 10.1038/s41417-018-0011-8. Epub 2018 May 3.

PMID:
29720674
35.

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT.

Griffin SJ, Bethel MA, Holman RR, Khunti K, Wareham N, Brierley G, Davies M, Dymond A, Eichenberger R, Evans P, Gray A, Greaves C, Harrington K, Hitman G, Irving G, Lessels S, Millward A, Petrie JR, Rutter M, Sampson M, Sattar N, Sharp S.

Health Technol Assess. 2018 Apr;22(18):1-64. doi: 10.3310/hta22180.

36.

NUT Carcinoma of the Salivary Glands: Clinicopathologic and Molecular Analysis of 3 Cases and a Survey of NUT Expression in Salivary Gland Carcinomas.

Agaimy A, Fonseca I, Martins C, Thway K, Barrette R, Harrington KJ, Hartmann A, French CA, Fisher C.

Am J Surg Pathol. 2018 Jul;42(7):877-884. doi: 10.1097/PAS.0000000000001046.

PMID:
29649019
37.

Pathologic confirmation of valve thrombosis detected by four-dimensional computed tomography following valve-in-valve transcatheter aortic valve replacement.

Gopal A, Ribeiro N, Squiers JJ, Holper EM, Black M, Gopal D, Szerlip M, Harrington KB, Potluri S, DiMaio JM, Brown DL, Grayburn PA, Mack MJ, Brinkman WT.

Glob Cardiol Sci Pract. 2017 Jun 30;2017(2):15. doi: 10.21542/gcsp.2017.15.

38.

Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer.

Henderson DR, Tree AC, Harrington KJ, van As NJ.

Medicines (Basel). 2018 Apr 5;5(2). pii: E32. doi: 10.3390/medicines5020032.

39.

Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?

Escalon JG, Harrington KA, Plodkowski AJ, Zheng J, Capanu M, Zauderer MG, Rusch VW, Ginsberg MS.

J Comput Assist Tomogr. 2018 Jul/Aug;42(4):601-606. doi: 10.1097/RCT.0000000000000727.

PMID:
29613986
40.

Seasonal micro-migration in a farm-island population of striated caracaras (Phalcoboenus australis) in the Falkland Islands.

Harrington KJ, Pole-Evans S, Reeves M, Bechard M, Bobowski M, Barber DR, Rexer-Huber K, Lecomte N, Bildstein KL.

Mov Ecol. 2018 Mar 30;6:4. doi: 10.1186/s40462-018-0122-8. eCollection 2018.

41.

Delta/mu opioid receptor interactions in operant conditioning assays of pain-depressed responding and drug-induced rate suppression: assessment of therapeutic index in male Sprague Dawley rats.

Cone K, Lanpher J, Kinens A, Richard P, Couture S, Brackin R, Payne E, Harrington K, Rice KC, Stevenson GW.

Psychopharmacology (Berl). 2018 May;235(5):1609-1618. doi: 10.1007/s00213-018-4876-x. Epub 2018 Mar 23.

PMID:
29572653
42.

Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study.

Rooney KP, Miah AB, Bhide SA, Guerrero-Urbano MT, Sharabiani MT, Newbold KL, Grove L, Harrington KJ, Nutting CM.

Radiother Oncol. 2018 Apr;127(1):43-48. doi: 10.1016/j.radonc.2018.02.002. Epub 2018 Mar 7.

PMID:
29525412
43.

Quantitative characterization of endoscopic imaging fibers.

Wood HAC, Harrington K, Stone JM, Birks TA, Knight JC.

Opt Express. 2017 Feb 6;25(3):1985-1992. doi: 10.1364/OE.25.001985.

PMID:
29519047
44.

Response to a Request for Clarification Regarding the Advanced Radiotherapy Technologies Network (ART-NET).

Faivre-Finn C, Harrington K.

Clin Oncol (R Coll Radiol). 2018 Jun;30(6):391-393. doi: 10.1016/j.clon.2018.01.021. Epub 2018 Mar 2. No abstract available.

PMID:
29478733
45.

HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.

Martins CD, Da Pieve C, Burley TA, Smith R, Ciobota DM, Allott L, Harrington KJ, Oyen WJG, Smith G, Kramer-Marek G.

Clin Cancer Res. 2018 Apr 15;24(8):1853-1865. doi: 10.1158/1078-0432.CCR-17-2754. Epub 2018 Feb 6.

PMID:
29437790
46.

Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.

Yip K, Melcher A, Harrington K, Illidge T, Nobes J, Webster A, Smith D, Lorigan P, Nathan P, Larkin J.

Clin Oncol (R Coll Radiol). 2018 Apr;30(4):201-203. doi: 10.1016/j.clon.2018.01.001. No abstract available.

PMID:
29402599
47.

Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy.

Dean J, Wong K, Gay H, Welsh L, Jones AB, Schick U, Oh JH, Apte A, Newbold K, Bhide S, Harrington K, Deasy J, Nutting C, Gulliford S.

Clin Transl Radiat Oncol. 2018 Jan;8:27-39. doi: 10.1016/j.ctro.2017.11.009. Epub 2017 Nov 21.

48.

Comparison of Baseline Characteristics and Outcomes in Men Versus Women With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.

Sannino A, Szerlip M, Harrington K, Schiattarella GG, Grayburn PA.

Am J Cardiol. 2018 Apr 1;121(7):844-849. doi: 10.1016/j.amjcard.2017.12.020. Epub 2018 Jan 10.

PMID:
29397106
49.

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Khan AA, Paget JT, McLaughlin M, Kyula JN, Wilkinson MJ, Pencavel T, Mansfield D, Roulstone V, Seth R, Halle M, Somaiah N, Boult JKR, Robinson SP, Pandha HS, Vile RG, Melcher AA, Harris PA, Harrington KJ.

Sci Transl Med. 2018 Jan 24;10(425). pii: eaar2041. doi: 10.1126/scitranslmed.aar2041.

50.

Practice patterns for the radical treatment of nasopharyngeal cancer by head and neck oncologists in the United Kingdom.

Petkar I, Bhide S, Newbold K, Harrington K, Nutting C.

Br J Radiol. 2018 May;91(1085):20170590. doi: 10.1259/bjr.20170590. Epub 2018 Feb 13.

PMID:
29360397

Supplemental Content

Loading ...
Support Center